Cellectar Biosciences reports FY2025 net loss $21.8M, cash $13.2M; plans EMA submission Q3 2026

Cellectar Biosciences, Inc.

Net loss $21.8M ($8.35/share) vs $44.6M ($36.52/share) in 2024; company pre-revenue.
Cash $13.2M at Dec 31, 2025, expected to fund operations into Q3 2026.
Plans to submit Conditional Marketing Authorization for iopofosine I 131 to EMA in Q3 2026.
Initiated Phase 1b study of CLR 125 in triple negative breast cancer; early data mid-2026.
Received FDA Breakthrough Therapy Designation for iopofosine I 131 in relapsed/refractory WM.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.